Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis

Abstract

AbstractBackgroundDupilumab has shown to be an effective and safe treatment for patients with moderate‐to‐severe atopic dermatitis (AD).ObjectiveTo evaluate the predictive factors of response (PRF) in patients with moderate‐to‐severe AD treated with dupilumab.MethodsObservational, retrospective and multicentre study conducted on adult patients diagnosed with moderate‐to‐severe AD treated with dupilumab, with a post‐treatment follow‐up of at least 16 weeks. The primary endpoints were EASI‐75 and the IGA scale at week 52.ResultsA total of 198 patients were included in the analysis. Mean age was 38 ± 15.1 years and 116 (58.6%) were men. The most prevalent AD‐predominant phenotypes were flexural eczema (45.3%), head‐and‐neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI‐75 and 119 (93.0%) achieved an improvement in ≥2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI‐75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of ≥2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049).ConclusionsDupilumab was an effective treatment in patients with moderate‐to‐severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI‐75 and an improvement of ≥2 points in the IGA scale, respectively, at week 52.